Age 40 Years and Under Does Not Confer Superior Prognosis in Patients with Multiple Myeloma Undergoing Upfront Autologous Stem Cell Transmplant

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 6, 2009, Pages 686-693

  Cheema, Parneet K ^a   Zadeh, Sahar ^a   Kukreti, Vishal ^a   Reece, Donna ^a   Chen, Christine ^a   Trudel, Suzanne ^a   Mikhael, Joseph ^a  

^a MAYO CLINIC   (United States)

Author keywords

Autologous stem cell transplantation; Multiple myeloma; Young patients

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERFERON; MELPHALAN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY FAILURE; MALE; MORTALITY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; PLASMA CELL LEUKEMIA; PROGNOSIS; PROTEINURIA; RELAPSE; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE; LEUKEMIA, PLASMA CELL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASMS, SECOND PRIMARY; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 67349266016     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.02.013     Document Type: Article

References (54)

1. Kyle R.A. Long term survival in multiple myeloma. N Engl J Med 30 (1983) 314-316
2. Kyle R.A., Gertz M.A., Witzig T.E., et al. Review of 1072 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78 (2003) 21-33
3. Blade J., Kyle R.A., and Griepp P.R. Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years. Br J Haematol 93 (1996) 345-351
4. Ludwig H., Durie B.G.M., Bolejack V., et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood 111 (2008) 4039-4047
5. Mileshkin L., Biagi J.J., Mitchell P., et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 102 (2003) 69-77
6. Garcia-Sanz R., Gonzalez-Fraile M.I., Mateo G., et al. Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients. Int J Cancer 112 (2004) 884-889
7. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111 (2008) 2516-2520
8. Sagaster V., Kaufmann H., Odelga V., et al. Chromosomal abnormalities of young multiple myeloma patients (<45 yr) are not different from those of other age groups and are independent of stage according to the international staging system. Eur J Haematol 78 (2007) 227-234
9. Hewell G.M., and Alexanian R. Multiple myeloma in young persons. Ann Intern Med 84 (1976) 441-443
10. Lazarus H.M., Kellermeyer R.W., Aikawa M., and Herzig R.H. Multiple myeloma in young men: clinical course and electron microscopic studies of bone marrow plasma cells. Cancer 46 (1980) 1397-1400
11. Geetha N., Jayaprakash M., Rekhanair A., and Ramachandran K. Plama cell neoplasms in young. Br J Radiol 72 (1999) 1012-1015
12. Blade J., San Miguel J.F., Alcala A., et al. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. J Clin Oncol 11 (1993) 1165-1171
13. Greipp P.R., and Lust J.A. O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2 microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 81 (1993) 3382-3387
14. Salmon S.E., Tesh D., Crowley J., et al. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. J Clin Oncol 8 (1990) 1575-1584
15. Attal M., Harousseau J.L., Stoppa A.M., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335 (1996) 91-97
16. Child J.A., Morgan G.J., Davies F.E., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 348 (2003) 1875-1883
17. Blade J., Samson D., Reece D., et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 102 (1998) 1115-1123
18. Grogan T.M., Muller-Hermelink H.K., Van C.B., Harris N.L., and Kyle R.A. World Health Organization classification tumours of haematopoietic and lymphoid tissues (2001), IARC Press, Lyon, France 142-156
19. Vescio R., Schiller G., Stewart A.K., et al. Multicenter phase III trial to evaluate CD34+ selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood 93 (1999) 1858-1868
20. Ameis A., Ko H.S., and Pruzanski W. M components-a review of 1242 cases. Can Med Assoc J 114 (1976) 889-895
21. Hobbs J.R. Immunochemical classes of myelomatosis. Including data from a therapeutic trial conducted by a Medical Research Council working party. Br J Haematol 16 (1969) 599-606
22. Blade J., and Kyle R.A. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 13 (1999) 1259-1272
23. Desikan R., Barlogie B., Sawyer J., et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. Blood 95 (2000) 4008-4010
24. Dimopoulos M.A., Palumbo A., Delasalle K.B., et al. Primary plasma cell leukaemia. Br J Haematol 88 (1994) 754-759
25. Garcia-Sanz R., Orfao A., Gonzalez M., et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetics characteristics. Blood 93 (1999) 1032-1037
26. Noel P., and Kyle R.A. Plasma cell leukemia: an evaluation of response to therapy. Am J Med 83 (1987) 1062-1068
27. Blade J., Lopez-Guillermo A., Bosch F., et al. Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haematol 88 (1994) 117-121
28. Durie B.G., Jacobson J., Barlogie B., and Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol 22 (2004) 1857-1863
29. Witzig T.E., Gertz M.A., Lust J.A., and Kyle R.A. O'Fallon WM, Greipp PR. Peripheral blood monoclonal plasma cells as a predictor of survival in patients with multiple myeloma. Blood 88 (1996) 1780-1787
30. Cunningham D., Powles R., Malpas J., et al. A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results. Br J Haematol 102 (1998) 495-502
31. Barlogie B., Tricot G., Anaissie E., et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354 (2006) 1021-1030
32. Attal M., Harousseau J.L., Leyvraz S., et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108 (2006) 3289-3294
33. Goldschimidt H., Sonneveld P., Cremer F.W., et al. Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol 82 (2003) 654-659
34. Berenson J.R., Crowley J.J., Grogan T.M., et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 99 (2002) 3163-3168
35. Goldschmidt H. Single vs double high-dose therapy in multiple myeloma: second analysis of the GMMG-HD2 Trial. Haematologica 90 (2005) PL8.02
36. Attal M., Harousseau J.L., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349 (2003) 2495-2502
37. Cavo M.C.C., Zamagni E., Tosi P., et al. Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma. Blood 104 (2004) 536
38. van der Holt B., Sonneveld P., Segeren C.M., Vellenga E., et al. Intensive versus double intensive therapy in untreated multiple myeloma: update analysis of the randomized phase III HOVON 24 study. Haematologica 90 (2005) PL 8.01
39. Kroger N., Schwerdtfeger R., Kiehl M., et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100 (2002) 755-760
40. Maloney D.G., Molina A.J., Sahebi F., et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 102 (2003) 3447-3454
41. Rosinol L., Perez-Simon J.A., Sureda A., et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 112 (2008) 3591-3593
42. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 356 (2007) 1110-1120
43. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107 (2006) 3474-3480
44. Rajkumar S.V., Blood E., Vesole D., et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 24 (2006) 431-436
45. Cavo M., Zamagni T.P., et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106 (2005) 35-39
46. Macro M., Divine M., Uzunban Y., et al. Dexamethasone + thalidomide compared to VAD as pre-transplant treatment in newly diagnosed multiple myeloma: a randomized trial [abstract]. Blood (2006) 108 (Abstract #22)
47. Lokhorst H.M., Schidt-Wolf I., Sonneveld P., et al. Thalidomide in induction treatment increases the very good partial remission rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 93 (2008) 124-127
48. Morgan G.J., Davies F.E., and Owen R.G. Thalidomide combinations improves response rate: results of the MRC IX study [abstract]. Blood (2007) 110 (Abstract #1051)
49. Harousseau J.L., Mathiot C., Attal M., et al. Velcade/dexamethasone versus VAD as induction treatment prior to autologous stem cell transplantation in newly diagnosed patients: updated results of the IFM 2005/01 trial [abstract]. Blood (2007) 110 (Abstract #139)
50. Lacy M.Q., Gertz M.A., Dispenzieri A., et al. Long-term results of response to therapy, time to progression and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc 82 (2007) 1179-1184
51. Moreau P., Facon T., Attal M., et al. Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone due Myelome 9502 randomized trial. Blood 99 (2002) 731-735
52. Barlogie B., Jagannath S., Desikan K.R., et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93 (1999) 55-65
53. Lahuerta J.J., Martinez-Lopez J., Grande C., et al. Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish registry for transplantation in multiple myeloma. Br J Haematol 109 (2000) 138-147
54. Griepp P.R., San Miguel J., Durie B.G.M., et al. International staging system for multiple myeloma. J Clin Oncol 23 (2005) 3412-3420